Beyond Air, Inc. (XAIR) Fair Value 2026

XAIR · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 4 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-08-28, Beyond Air, Inc. (XAIR) trades at $4.48, versus a $19.21 median fair value across its 4 active models — 328.7% above the current price. QOC: 5.8/10. Value Trap Risk: 24/100 (SAFE). 4/13 models active.

Key Facts

Ticker
XAIR
Price
$4.48
Quality Score
5.8/10
Value Trap Risk
24/100
Models Active
4/13
Last Updated
Strength: CUCE Ensemble suggests +372.0% upside with 16% confidence
Risk: Limited model coverage (4/13) may reduce confidence

Is Beyond Air, Inc. (XAIR) Undervalued or Overvalued in 2026?

According to CirclFi’s 4-model valuation engine, Beyond Air, Inc. (XAIR) appears undervalued as of : the median of 4 independent fair value estimates is $19.21, 328.7% above the current price of $4.48. Estimates range from $5.85 to $25.85. XAIR scores 5.8/10 on fundamental quality and 24/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. XAIR’s +328.7% gap is wider than that market norm, and the Medical Devices sector median is -43.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Beyond Air, Inc. Stock in 2026? →

What Fair Value Does Each Model Give XAIR?

4 Intrinsic Value Models vs. Current Price ($4.48)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $21.15 +372.0%
Asset-Based · High Conviction
 $17.27 +285.4%
Unlock the Full Matrix

Access 2 additional models including PWERM, Regime Cross-Sectional.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 4 Models →

Cancel anytime · No contracts · Instant access

What Is XAIR's Fair Value Range?

Spread across 4 independent models · $5.85 to $25.85

CirclFi's 4 active models place Beyond Air, Inc. (XAIR) between $5.85 and $25.85 per share, a spread of 104% of the median. The median of that range — $19.21 — is the fair value CirclFi publishes for XAIR, against a current price of $4.48.

Low · Regime CrossHigh · PWERM
$5.85median $19.21$25.85
Where the range comes from
Most bearish modelRegime Cross-Sectional$5.85
Most bullish modelPWERM$25.85
Model agreement4 bullish · 0 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for XAIR. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on XAIR, not a CirclFi price target. How each model works →

What Is Beyond Air, Inc. (XAIR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Beyond Air, Inc. is potentially undervalued at its current price of $4.48. Based on our 13-model framework, Beyond Air, Inc.'s intrinsic value is estimated at a median fair value of $19.21 — representing +328.7% implied upside — with 4 out of 4 active models confirming this thesis. Model dispersion is worth noting: PWERM targets $25.85 (+477.1%), versus Regime Cross at $5.85 (+30.5%). This +446.6% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About XAIR?

4 of 13 models are currently active for XAIR. All 4 active models suggest the stock trades below fair value. Taken together, their median fair value for XAIR is $19.21 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does XAIR Rank in Medical Devices?

Among 159 Medical Devices stocks, XAIR ranks #96 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For Beyond Air, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is XAIR a Value Trap?

CirclFi's Value Trap algorithm assigns XAIR a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

4 of 13 models are active for Beyond Air, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Beyond Air, Inc. scores 5.8 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +446.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every XAIR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across XAIR's 4 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Beyond Air, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

LABStandard BioTools Inc.QOC 5.9OWLTOwlet, Inc.QOC 5.8BTCYBiotricity, Inc.QOC 6.0QDELQuidelOrtho CorporationQOC 5.8SSIISS Innovations International, Inc.QOC 6.0ADMTADM Tronics Unlimited, Inc.QOC 5.8RBOTVicarious Surgical Inc.QOC 4.6EWEdwards Lifesciences CorporationQOC 8.7NEOGNeogen CorporationQOC 6.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: LAB · OWLT · BTCY · QDEL · SSII · ADMT · RBOT · EW · NEOG · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to XAIR?

7 companies across all industries closest to XAIR’s Quality of Company score of 5.8/10.

RPAYRepay Holdings CorporationQOC 5.8MBIMBIA Inc.QOC 5.8IRENIREN LimitedQOC 5.8NKTRNektar TherapeuticsQOC 5.8ANDGAndersen Group Inc.QOC 5.9ATGLAlpha Technology Group LimitedQOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RPAY · MBI · IREN · NKTR · ANDG · ATGL · NVDA

Where Does XAIR Sit in CirclFi's Medical Devices Rankings?

XAIR is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Beyond Air, Inc.’s Valuation?

What is Beyond Air, Inc.'s intrinsic value in 2026?

CirclFi puts Beyond Air, Inc. (XAIR)'s intrinsic value at $19.21 — the median of 4 independent model estimates as of 2026-08-28, ranging from $5.85 to $25.85. The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is XAIR overvalued or undervalued right now?

At $4.48, 4 of 4 active models suggest XAIR may be undervalued, while 0 indicate potential overvaluation. The median of all 4 fair value estimates is $19.21, 328.7% above the current price of $4.48 — a consensus view that XAIR is undervalued. The assessment depends on which methodology best fits Beyond Air, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.8 mean for XAIR?

Beyond Air, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on XAIR?

CirclFi analyzes XAIR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 4 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on XAIR?

Of the 4 models currently active on XAIR, PWERM is the most bullish at $25.85 per share, and Regime Cross-Sectional is the most bearish at $5.85. CirclFi's published fair value for XAIR is the median of that range, $19.21, not either extreme. The gap between the two ends equals 104% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is XAIR a value trap in 2026?

Beyond Air, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 4-model valuation engine, Beyond Air, Inc. (XAIR) has a median fair value of $19.21 — 328.7% above the current price of $4.48 — as of 2026-08-28.” Source: circlfi.com/stock/XAIR/ · Methodology
Primary sources for this XAIR valuation
  • Financial statements: Beyond Air, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001641631) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for XAIR as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 4 mathematical frameworks give you clarity on XAIR.

Unlock All 4 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

2 models hidden for XAIR Unlock All 4 — $39/mo